Halozyme Therapeutics

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development and commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. The firm products include rHuPH20, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Halozyme posts record revenue in 2022, eyes growth opportunities

Halozyme's strong financial performance in 2022 and positive revenue guidance for 2023 reflect a robust growth trajectory.
While facing integration challenges from acquisitions and potential competition, the company's strategic priorities and market engagement remain strong.
Exploring new collaborations, advancing product development, and maintaining a competitive edge present key opportunities for Halozyme.
Overall, Halozyme's proactive approach to growth and market dynamics positions it well for future success in the biopharmaceutical industry.

Halozyme reports robust Q1 earnings, poised for continued growth

Halozyme's strong Q1 performance and robust pipeline position them for continued revenue growth and leadership in subcutaneous drug delivery.
Challenges include regulatory impacts and legal uncertainties, but opportunities in new agreements, partnerships, and investments offer avenues for future growth.
Overall, Halozyme's strategic focus on innovation and revenue diversification bodes well for their long-term success and financial stability.

Halozyme reports robust Q2 growth, eyes new partnerships for revenue

Halozyme's Q2 2023 earnings call showcased strong financial performance, innovative product developments, and a positive outlook for revenue growth. The company's focus on expanding partnerships, maintaining revenue durability, and strategic capital allocation positions it well for future success in the biopharmaceutical market.

Halozyme excels in Q3, raises guidance, eyes market expansion

Halozyme's Q3 performance reflects financial strength and operational resilience, supported by strategic partnerships and revenue growth.
The company's focus on shareholder value through accelerated buybacks and commitment to innovation positions them for sustained success.
While challenges like market competition exist, Halozyme's opportunities in market expansion and revenue growth paint a positive outlook for the future.

Halozyme posts record earnings, eyes strategic growth opportunities ahead

Halozyme's strong financial results and positive outlook for 2024 position the company for continued growth and value creation.
Addressing challenges around market adoption and reimbursement processes will be key to unlocking the full potential of subcutaneous products.
Strategic partnerships, new product launches, and a focus on shareholder value enhancement underscore Halozyme's commitment to sustainable growth.

Halozyme reports robust Q1 growth, navigates biosimilar challenges

Halozyme's Q1 2024 performance demonstrated strong financial growth driven by royalties and milestone payments, supported by operational achievements and strategic capital allocation.
While facing challenges such as biosimilar competition and partnership complexities, the company remains well-positioned to capitalize on opportunities in subcutaneous delivery preferences and market expansion.
Overall, Halozyme's focus on revenue diversification, partnership expansion, and operational excellence sets a positive trajectory for sustained growth and resilience in the biopharmaceutical sector.

Halozyme posts strong Q3 results, raises guidance amid growth opportunities

Halozyme Therapeutics reported a stellar Q3 performance with significant revenue growth and raised guidance across key financial metrics. The company's partnerships, product portfolio, and strong financial position underscore its growth potential and market resilience. Halozyme is well-positioned to capitalize on opportunities for expansion and innovation in the biopharmaceutical sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

SAN DIEGO, Dec. 23, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission has approved Roche's Phesgo®, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with Halozyme's ENHANZE® technology, administered...

Halozyme Announces Roche Receives European Commission Approval For Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Breast Canc

BioCryst Pharmaceuticals

QuidelOrtho Corp

Teladoc

Acceleron Pharma

The U.S. healthcare sector emerged as one of the very few sectors that has been able to turn the misfortunes of COVID-19 pandemic to its advantage. The ongoing COVID-19 outbreak and an aging U.S. population has spurred demand for healthcare products and services. The sector continues to undertake several technological advancements for boosting the digital space.

5 Healthcare Stocks That Fared Well in 2020 Amid the Pandemic

Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy?

Halozyme has settled into its role as a royalty cash machine after transitioning away from a drug discovery company, and the immediate future looks very bright. With 5 products currently on the market and 11 trials ongoing using its technology, growing its royalty revenue and profits looks certain.

Halozyme: 7 Years Of Royalty Bliss Coming; Afterwards, Questions To Answer

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?

Why Is Halozyme Therapeutics (HALO) Up 28.4% Since Last Earnings Report?

What Makes Halozyme Therapeutics (HALO) a Strong Momentum Stock: Buy Now?

Horizon (HZNP) inks deal to get an exclusive access to Halozyme's ENHANZE drug delivery technology for subcutaneous formulation of medicines targeting IGF-1R.

Horizon (HZNP) and Halozyme Ink Deal for ENHANZE Technology

SAN DIEGO, Nov. 23, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it is updating 2020 financial guidance to reflect the signing of a global collaboration and license agreement with Horizon Therapeutics plc. The Company is raising full year 2020...

Halozyme Raises Full Year 2020 Guidance

Horizon Pharma

DUBLIN & SAN DIEGO--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that gives Horizon exclusive access to Halozyme's ENHANZE® drug delivery technology for subcutaneous (SC) formulation of medicines targeting IGF-1R. Horizon intends to use ENHANZE® to develop a SC formulation of TEPEZZA (teprotumumab-trbw), indicated for the treatment of Thyroid Eye Disease, a serious, progressiv

Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology

SAN DIEGO, Nov. 18, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will participate in a fireside chat presentation for the Piper Sandler 32nd Annual Virtual Healthcare Conference. The virtual...

Halozyme To Participate In Fireside Chat For The Piper Sandler 32nd Annual Virtual Healthcare Conference

SAN DIEGO, Nov. 13, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Roche's Phesgo®, a fixed-dose combination of Perjeta®...

Halozyme Announces CHMP Recommends EU Approval Of Roche's Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For HER2-Positive Breast Cancer

SAN DIEGO, Nov. 12, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the Janssen Pharmaceutical Companies submitted regulatory applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval of the...

Halozyme Announces Janssen Submission Of Applications In US And EU Seeking Approval Of DARZALEX FASPRO™/ DARZALEX® Subcutaneous (SC) Formulation Utilizing ENHANZE® Technology, Combination With Pomalidomide And Dexamethasone For Patients With Relapsed Or R

SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that studies sponsored by Janssen Research & Development, LLC (Janssen) evaluating subcutaneous (SC) daratumumab utilizing ENHANZE® will be the subject of presentations at the upcoming...

Halozyme Announces Upcoming Data Presentations at American Society of Hematology Annual Meeting For APOLLO and ANDROMEDA Phase 3 Studies By Janssen Evaluating Subcutaneous Daratumumab Utilizing ENHANZE®

The shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)  are up 3.6% to trade at $32.77 at last check, after earlier hitting an all-time high of $33.23.

Reliable Biotech Stock Signal Flashing Again

Halozyme Therapeutics boosted its EPS and sales guidance for the year, buoyed by partnerships with big drugmakers such as Roche and Johnson & Johnson, sparking HALO stock to a record high. The post Halozyme Therapeutics Deals With Drug Giants Spark Stock To New High appeared first on Investor's Business Daily.

Halozyme Therapeutics Deals With Drug Giants Spark Stock To New High

Halozyme (HALO) reports better-than-expected third-quarter results. The company raises outlook for the year anticipating higher royalties.

Halozyme (HALO) Q3 Earnings Top, 2020 View Up, Stock Rises

Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q3 2020 Results - Earnings Call Transcript

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q3 2020 Results - Quick Version Earnings Call Transcript

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth

SAN DIEGO, Oct. 6, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Halozyme and argenx are expanding their existing global collaboration and license agreement that was signed in February 2019. Under the newly announced expansion, argenx gained the...

Halozyme Announces Expansion Of Collaboration And License Agreement With argenx For ENHANZE® Technology

SAN DIEGO, Sept. 10, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Halozyme Announces Janssen Submission For FDA Approval Of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) For The Treatment Of Patients With Light Chain (AL) Amyloidosis

Halozyme Therapeutics (HALO) Down 1.6% Since Last Earnings Report: Can It Rebound?

SAN DIEGO, Sept. 2, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Halozyme To Participate In 2020 Wells Fargo Virtual Healthcare Conference

Halozyme (HALO) reports lower-than-expected Q2 earnings. Shares down.

Halozyme (HALO) Q2 Earnings and Revenues Miss Estimates

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q2 2020 Results - Earnings Call Transcript

News for Halozyme Therapeutics Stock (HALO)